| Literature DB >> 19568313 |
Abstract
Two new, rapid, precise, accurate and specific chromatographic methods were described for the simultaneous determination of olmesartan medoxomil and hydrochlorothiazide in combined tablet dosage forms. The first method was based on reversed phase liquid chromatography using an Eurosphere 100 RP C18 column (250 x 4.6 mm ID, 5 mum). The mobile phase was methanol-0.05% o-phosphoric acid (60:40 v/v) at a flow rate of 1.0 mL min(-1). Commercially available tablets and laboratory mixtures containing both drugs were assayed and detected using a UV detector at 270 nm. The second method involved silica gel 60 F(254) high performance thin layer chromatography and densitometric detection at 254 nm using acetonitrile-ethyl acetate-glacial acid (7:3:0.4 v/v/v) as the mobile phase. Calibration curves ranged between 200-600 and 125-375 ng spot(-1) for olmesartan and hydrochlorothiazide, respectively.Entities:
Year: 2009 PMID: 19568313 PMCID: PMC2701495 DOI: 10.1365/s10337-009-1094-z
Source DB: PubMed Journal: Chromatographia ISSN: 0009-5893 Impact factor: 2.044
Fig. 1Representative HPLC chromatogram and structures of olmesartan medoxomil OLM (20 μg mL−1) and hydrochlorothiazide HCT (12.5 μg mL−1)
Calibration graphs and system suitability (n = 5) of olmesartan medoxomil and hydrochlorothiazide by RP-LC and HPTLC
| Parameter | RP-LC | HPTLC | ||
|---|---|---|---|---|
| OLM | HCT | OLM | HCT | |
| Linearity range | 4–24 μg mL−1 | 2.5–15 μg mL−1 | 200–600 ng spot−1 | 125–375 ng spot−1 |
| Regression equation | ||||
| Slope | 24,055 | 104,515 | 8.79 | 9.18 |
| Intercept | 688.3 | −1,915.7 | 184.12 | 441.13 |
| Coefficient of correlation | 0.9998 | 0.9999 | 0.9992 | 0.994 |
| Limit of detection (LOD) | 0.44 μg mL−1 | 0.21 μg mL−1 | 20.20 ng spot−1 | 18.65 ng spot−1 |
| Limit of quantitation (LOQ) | 1.32 μg mL−1 | 0.63 μg mL−1 | 61.07 ng spot−1 | 57.24 ng spot−1 |
| System suitability | ||||
| Asymmetry | 1.75 | 1.22 | – | – |
| No. of theoretical plates | 2,313 | 4,976 | – | – |
| Capacity factor | 12.8 | 34.33 | – | – |
Results of analysis of commercially available tablets containing olmesartan medoxomil and hydrochlorothiazide by RP-LC and HPTLC
| Method | RP-LC | HPTLC | ||
|---|---|---|---|---|
| OLM | HCT | OLM | HCT | |
| Labeled claim mg tablet−1 | 20 | 12.5 | 20 | 12.5 |
| % mean ( | 100.24 | 100.1 | 100.09 | 99.77 |
| Standard deviation | 0.2926 | 0.3354 | 1.3123 | 1.6030 |
| SE | 0.1462 | 0.1677 | 0.6562 | 0.8015 |
| RSD (%) | 0.2919 | 0.3351 | 1.3112 | 1.6067 |
SE standard error
Fig. 2Densitogram of olmesartan medoxomil (200 ng spot−1, Rf 0.44) and hydrochlorothiazide (125 ng spot−1, Rf 0.64)